Pancreatic Cancer Research

ResearcherMiami UniversityActive in the last 2 years

Ian M. Loveless

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8796-8799, 0000-0003-4645-6559; OpenAlex author ID A5006312944, A5060106054. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 9

  1. Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
  2. Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments. Co-author DOI 10.1158/0008-5472.can-25-2748↗
  3. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  4. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  5. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  6. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  7. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Co-author DOI 10.1172/jci.insight.174264↗
  8. Corrigendum to "scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis" [Cancer Let… Co-author DOI 10.1016/j.canlet.2024.217071↗
  9. scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis. Co-author DOI 10.1016/j.canlet.2023.216149↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nina G. Steele · 7 shared papers, 2025–2026 · strength 1.41
  2. Howard C. Crawford · 7 shared papers, 2023–2026 · strength 1.33
  3. Debora Barbosa Vendramini Costa · 3 shared papers, 2025–2026 · strength 0.60
  4. Ralph A. Francescone III · 3 shared papers, 2025–2026 · strength 0.60
  5. Bin Chen · 3 shared papers, 2023–2026 · strength 0.56
  6. Samantha B. Kemp · 3 shared papers, 2025 · strength 0.56
  7. Naomi Yamamoto · 2 shared papers, 2025–2026 · strength 0.41
  8. Stephanie Dobersch · 2 shared papers, 2025–2026 · strength 0.41
  9. Sita Kugel · 2 shared papers, 2025–2026 · strength 0.41
  10. Faiyaz Notta · 2 shared papers, 2025–2026 · strength 0.41
  11. Sunil R. Hingorani · 2 shared papers, 2025–2026 · strength 0.41
  12. Marina Pasca di Magliano · 2 shared papers, 2025 · strength 0.39
  13. Daniel James Salas-Escabillas · 2 shared papers, 2025–2026 · strength 0.38
  14. Ling Huang · 2 shared papers, 2025–2026 · strength 0.38
  15. David Kwon · 2 shared papers, 2025–2026 · strength 0.38
  16. Yuesong Wu · 2 shared papers, 2025–2026 · strength 0.38
  17. Kailee M. Hartway · 2 shared papers, 2025–2026 · strength 0.38
  18. Qing‐Sheng Mi · 2 shared papers, 2023–2024 · strength 0.35
  19. Qijun Yi · 2 shared papers, 2023–2024 · strength 0.35
  20. Oliver Gene McDonald · 1 shared paper, 2026 · strength 0.23
  21. Nikki K. Lytle · 1 shared paper, 2026 · strength 0.23
  22. Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.23
  23. Austin D. Silva · 1 shared paper, 2026 · strength 0.23
  24. David K. Imagawa · 1 shared paper, 2026 · strength 0.23
  25. Rima Singh · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.